DRUG
Bright Minds BiosciencesDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
A robust positive BMB-101 readout and subsequent partner interest would validate mechanism and drive rapid re-rating toward premium targets; analysts' high cases reflect successful clinical and commercial execution.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -2.2.
What can break
Insufficient cash runway leading to dilution
Momentum
25
Value
41
Sentiment
73
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $88.00 · Bull $140.00 · Bear $60.00
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-01-17 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $149.70
Why
Momentum25 · Δ7d +11.6
Value41 · Δ7d +0.0
Sentiment73 · Δ7d -2.2
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
25
26% active weight
Current posture
7d trendImproving
Δ7d
+11.6
Δ21d
+12.8
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
73
34% active weight
Current posture
7d trendSoftening
Δ7d
-2.2
Δ21d
-21.3
Why this grade
Composite grade D. Momentum 25.1 / Value 41.1 / Sentiment 73.1
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$730.22M
Beta
-0.59
Shares Out
9.79M
P/E (TTM) · Derived
-58.7
P/S (TTM)
-
P/FCF (TTM) · Derived
-42.61
Rev YoY
-
EPS YoY
+172.2%
Gross Margin
-
Op Margin
-
Net Debt
-$59.5M
Current Ratio
81.48
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology